Waters Launches Charge Detection Mass Spectrometry Technology
Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), enabling accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles.
The technology can distinguish between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample, addressing the challenges of analyzing large and heterogeneous drug modalities.
With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, the CDMS delivers unmatched measurement and characterization for the broadest range of mega-mass biomolecules.
Learn about our Editorial Policies.
Author's summary: Waters launches CDMS technology for biotherapeutics development.